PMDA follow-up alert: severe hypocarnitinemia and hypoglycemia with pivoxil-containing antibiotics
「PMDAからの医薬品適正使用のお願い」に「ピボキシル基を有する抗菌薬投与による小児等の重篤な低カルニチン血症、重篤な低血糖について（続報）」を掲載しました
Published: 2026-06-30 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2026-06-30, the Pharmaceuticals and Medical Devices Agency (PMDA) announced a follow-up alert in its proper use of medicines series. The alert concerns severe hypocarnitinemia and severe hypoglycemia in children and others following administration of antibiotics containing a pivoxil group.
Business Impact
Healthcare professionals administering pivoxil-containing antibiotics and children and other patients receiving them may be affected by the safety issues highlighted in this follow-up alert.
Recommended Action
Review of the official PMDA follow-up alert could clarify the affected medicines, patient groups, and any updated precautions.